Crystallin aggregation is characterized by light scattering of large molecular aggregates due to their phase separation in the lens. Low-resolution biophysical studies using multiple techniques have characterized the folding, stability, binding, and aggregation of crystallins in the past but with limited access to their structure, dynamics, and interactions. In this Viewpoint, three schools of experimental structural biology, that is, X-ray crystallography, solution and solid-state NMR spectroscopy, and cryo-electron microscopy, combine to provide atomic resolution details of native crystallins, soluble oligomers, and insoluble amyloid fibrils and amorphous aggregates. Computational structural biology provides additional details on crystallin dynamics and the crucial intercrystallin interactions in these events. Our current understanding of the diverse structural biology of crystallins is consistent with multiple pathways of protein aggregation for different structural intermediates. This Viewpoint combines our efforts with those of others to elucidate the recent progress in these high-resolution studies and proposes an integrated structural biology approach to resolve the complex lens interactome. Overall, I discuss the outstanding questions and evaluate the experimental and theoretical caveats in the field.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/febs.15684 | DOI Listing |
PLoS One
January 2025
School of Health and Biomedical Sciences, RMIT University, Bundoora, Victoria, Australia.
The cytotoxic T-lymphocyte antigen-4 (CTLA4) is essential in controlling T cell activity within the immune system. Thus, uncovering the molecular dynamics of single nucleotide polymorphisms (SNPs) within the CTLA4 gene is critical. We identified the non-synonymous SNPs (nsSNPs), examined their impact on protein stability, and identified the protein sequences associated with them in the human CTLA4 gene.
View Article and Find Full Text PDFPLoS One
January 2025
Neuroscience Center, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia.
Hepatitis C Virus (HCV) is a blood borne pathogen that affects around 200 million individuals worldwide. Immunizations against the Hepatitis C Virus are intended to enhance T-cell responses and have been identified as a crucial component of successful antiviral therapy. Nevertheless, attempts to mediate clinically relevant anti-HCV activity in people have mainly failed, despite the vaccines present satisfactory progress.
View Article and Find Full Text PDFJ Med Chem
January 2025
Experimental Drug Development Centre, Chromos, Agency for Science, Technology and Research, 10 Biopolis Road, #05-01, Singapore 138670.
The discovery of molecular glues has made significant strides, unlocking new avenues for targeted protein degradation as a therapeutic strategy, thereby expanding the scope of drug discovery into territories previously considered undruggable. Pioneering molecules like thalidomide and its derivatives have paved the way for the development of small molecules that can induce specific protein degradation by hijacking the cellular ubiquitin-proteasome system. Recent advancements have focused on expanding the range of E3 ligases and target proteins that can be modulated by molecular glues.
View Article and Find Full Text PDFAnal Chem
January 2025
Department of Chemistry and Biochemistry, Ohio State University, Columbus, Ohio 43210, United States.
Native Mass Spectrometry (nMS) is a versatile technique for elucidating protein structure. Surface-Induced Dissociation (SID) is an activation method in tandem MS predominantly employed for determining protein complex stoichiometry alongside information about interface strengths. SID-nMS data can be collected over a range of acceleration energies, yielding Energy Resolved Mass Spectrometry (ERMS) data.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
January 2025
Cellular and Structural Physiology Laboratory, Advanced Research Initiative, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8510, Japan.
Pathogen mutations present an inevitable and challenging problem for therapeutics and the development of mutation-tolerant anti-infective drugs to strengthen global health and combat evolving pathogens is urgently needed. While spike proteins on viral surfaces are attractive targets for preventing viral entry, they mutate frequently, making it difficult to develop effective therapeutics. Here, we used a structure-guided strategy to engineer an inhibitor peptide against the SARS-CoV-2 spike, called CeSPIACE, with mutation-tolerant and potent binding ability against all variants to enhance affinity for the invariant architecture of the receptor-binding domain (RBD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!